NeuroPace price to book ratio NPCE

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 37.3×
5-year median: 14.5×
Against its 5-year history: 89th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.8× to 52.4×
Peer median: 3.1×

NeuroPace's price to book ratio is 37.3× as of Oct 23, 2026.

That is above its 5-year median of 14.5×, higher than on 89% of days in the last 5 years.

Over that time it ranged from 0.8× in Dec 2022 to 52.4× in May 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 3.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	37.3×	23.0×	43.0×
2025	28.8×	12.1×	52.4×
2024	32.4×	13.0×	35.0×
2023	16.6×	0.9×	16.6×
2022	0.9×	0.8×	3.1×
2021	3.0×	2.6×	6.5×

Against its peers

Companies in Medical - Instruments & Supplies nearest NeuroPace's size, closest first, today.

Company	Price to book ratio
NPCENeuroPace	37.3×
EMBCEmbecta	n/m
TCMDTactile Systems Technology	2.4×
MDXGMimedx	2.6×
MOVMovado	1.4×
INFUInfuSystem	4.7×
UTMDUtah Medical Products	1.9×
PDEXPro DEX	4.2×
IRMDIradimed	10.8×
STAAStaar Surgical	3.1×
BVSBioventus	5.5×
Peer median	3.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on NeuroPace

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.